Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27163592 | 0.77 | TSHR (0.45) | TSHRKDM4EALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL27163695 | 0.77 | TSHR (0.45) | TSHRKDM4EALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL15205884 | 0.77 | TSHR (0.45) | TSHRKDM4EALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL27242799 | 0.75 | TSHR (0.36) | TSHRKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL2487318 | 0.73 | LMNA (0.34) | LMNA | |
| SCHEMBL10204111 | 0.73 | KDM4E (0.35) | TSHRKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL15271360 | 0.72 | TSHR (0.41) | TSHRKDM4EALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL29171350 | 0.72 | DPP4 (0.53) | TSHRKDM4EALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL2299168 | 0.72 | DPP4 (0.53) | TSHRKDM4EALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL22558450 | 0.70 | TSHR (0.30) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117120439-A | FGFR3 inhibitor compounds | 伊莱利利公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-113227068-B | GLP-1R agonists and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2023-06-13 | — | — | CN | disclosed |
| CN-115776887-A | MDM2 degrading agents and uses thereof | 凯麦拉医疗公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-110678466-B | Diazanaphthalenes as HPK1 inhibitors | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-113015526-A | Spirocyclic 2, 3-dihydro-7-azaindole compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | disclosed |
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200207716-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2020-07-02 | — | — | US | disclosed |
| US-10414727-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-8710224-B2 | Heterocyclic compounds as CCR2B antagonists | ASTRAZENECA AB (SE) | 2014-04-29 | — | — | US | disclosed |
| US-20140038978-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | ASTRAZENECA AB (SE) | 2014-02-06 | — | — | US | disclosed |
| US-20120264762-A1 | Heterocyclic Compounds as CCR2 Antagonists | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | US | disclosed |
| US-20110195978-A1 | COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | PURDUE RESEARCH FOUNDATION (US) | 2011-08-11 | — | — | US | disclosed |
| US-20110136820-A1 | Heterocyclic Compounds as CCR2 Antagonists | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-7906645-B2 | Heterocyclic compounds as ccr2b antagonists | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| US-20090099156-A1 | Heterocyclic Compounds as Ccr2b antagonists | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| WO-2006072353-A1 | AZETIDINE-SUBSTITUTED PYRAZOLINES AS PAR-1 ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006072350-A1 | CYANOGUANIDINE-SUBSTITUTED PYRAZOLINES | BAYER HEALTHCARE AG (DE) | 2006-07-13 | — | — | WO | disclosed |
| US-6413964-B1 | 14-AMINO-14-(1-METHYL-1H-IMIDAZOL-5-YL)-8-OXA-2-THIA-1,18 -DIAZATETRACYCLO(16.2.2.1(3,7).1(9,13))TETRACOSA-3(24),4,6, 9(23),10,12-HEXAENE-10-CARBONITRILE 2,2-DIOXIDE, FOR EXAMPLE; USE IN RADIOTHERAPY, CHEMOTHERAPY AS SENSITIZER | MERCK & CO., INC. | 2002-07-02 | — | — | US | disclosed |
| WO-2001051125-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | MTOR, RICTOR, RPTOR | TSHR 4664/4885KDM4E 253/4885ALDH1A1 3942/4885 |
| US-20110195978-A1 | COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | PSEN2, PSEN1, CHAT | TSHR 4655/4885KDM4E 3427/4885ALDH1A1 1222/4885 |
| US-20120264762-A1 | Heterocyclic Compounds as CCR2 Antagonists | CCR2, CCR3, CXCR2 | TSHR 997/4885KDM4E 4370/4885ALDH1A1 3238/4885 |
| US-20110136820-A1 | Heterocyclic Compounds as CCR2 Antagonists | CCR2, CCR3, CXCR2 | TSHR 997/4885KDM4E 4370/4885ALDH1A1 3238/4885 |
| US-20140038978-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | CCR2, CCR3, CXCR2 | TSHR 1018/4885KDM4E 4220/4885ALDH1A1 3388/4885 |
| US-20090099156-A1 | Heterocyclic Compounds as Ccr2b antagonists | CCR2, CCR3, CXCR2 | TSHR 973/4885KDM4E 4195/4885ALDH1A1 3415/4885 |
| US-10414727-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | MTOR, RICTOR, RPTOR | TSHR 4664/4885KDM4E 253/4885ALDH1A1 3942/4885 |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | TSHR 4664/4885KDM4E 253/4885ALDH1A1 3942/4885 |
| US-20200207716-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | TSHR 4664/4885KDM4E 253/4885ALDH1A1 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.